# Infectious Diseases Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frédéric Chopin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI020-SYN
- Date: 2026-03-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ewa Kowalczyk-Grant, MD
- Calendar frame: modern shifted

- Requested by: Matthias Lindqvist, MD

## Reason for consultation

Suspected cavitary pulmonary tuberculosis in a 28-year-old pianist and piano teacher with three months of cough, blood-streaked sputum, night sweats, and weight loss, and a lifelong history of chest illness. Please confirm the diagnosis when the sputum results return, advise on the regimen, monitoring, and his return to teaching, and tell us whether cystic fibrosis or alpha-1 antitrypsin deficiency needs to be excluded. **S**

## History

Mr. Chopin, a 28-year-old pianist who teaches in his apartment, is seen at the request of Dr. Lindqvist three days after presenting with three months of cough, two weeks of blood-streaked sputum, night sweats, evening fevers, and weight loss. He has coughed up blood once more since. He has had recurrent coughs and fevers with colds since his teens, but he has never had a diagnosis of a chronic lung disease, nasal polyps, sinus disease, greasy stools, or liver disease. He has never been treated for tuberculosis and knows of no contact with drug-resistant disease. He takes no medicines and has no history of heart rhythm problems or fainting. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin and tired; temperature 37.6 °C, pulse 98; seen in an airborne infection isolation room |
| Ears, nose, and throat | No nasal polyps |
| Respiratory | Coarse crackles and bronchial breathing over the right upper zone; fine crackles at the left apex |
| Extremities | No clubbing |
| Musculoskeletal | Tendons non-tender |
| Neurological | Normal sensation in the fingers and feet |

BP 102/64 mmHg; pulse 98 bpm; respirations 18/min; temperature 37.6 °C; oxygen saturation 95% on room air; weight 48.4 kg; BMI 16.7 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Lindqvist's note; the chest X-ray and CT; three sputum smears (2+, 2+, 1+); the nucleic acid amplification test (Mycobacterium tuberculosis complex detected, rifampin resistance not detected); the interferon-gamma release assay (positive); HIV-1/2 antigen and antibody (negative); hepatitis B surface antigen and core antibody (negative) with surface antibody positive; hepatitis C antibody (negative); and the baseline blood count, liver and kidney tests, potassium, calcium, and magnesium. 

## Assessment

1. **Pulmonary tuberculosis, cavitary and smear-positive** (A15.0). Confirmed by a positive amplification test with three positive smears, in keeping with the cavity and the symptoms. No rifampin resistance. A positive interferon-gamma release assay supports the diagnosis but would not have excluded it if negative. Nontuberculous mycobacteria do not give a positive amplification test for the tuberculosis complex. Cultures, molecular tests for isoniazid and fluoroquinolone resistance, and phenotypic susceptibility are pending. **S**
2. **Choice of regimen**. He is eligible for the four-month regimen: age over 12, weight 48.4 kg, pulmonary disease only, HIV negative, no prolonged QT history or QT-prolonging medicines, normal potassium and magnesium, normal liver tests and creatinine, no earlier treatment, and specimens sent for susceptibility before the first dose. A cavity does not exclude it. Compared with the six-month regimen it shortens treatment by two months, which matters to him as a teacher and performer, at the cost of more tablets taken with food and the moxifloxacin precautions. He chose it after hearing both options. **S**
3. **Monitoring**. An electrocardiogram is not routinely needed, because he has no QT risk factors. His low weight and albumin justify one early liver check even without symptoms. Moxifloxacin can cause tendon injury and, with isoniazid, nerve damage, which would matter greatly to a pianist; both should be asked about at every visit and every observed dose. **S**
4. **Isolation and return to teaching**. He remains infectious until he has had at least two weeks of treatment, his symptoms are improving, and three sputum smears collected at least eight hours apart are negative. After that, with the health department's agreement, he can teach in person and needs no mask. **S**
5. **Cystic fibrosis and alpha-1 antitrypsin deficiency**. Neither is likely: the CT shows no bronchiectasis or emphysema, he has no sinus or pancreatic symptoms, and tuberculosis fully explains his illness. Because his lifelong chest illness raises the question and he wants it answered, a sweat chloride test and a serum alpha-1 antitrypsin level are reasonable and simple; a sweat chloride below 30 mmol/L makes cystic fibrosis unlikely. **S**
6. **Moderate protein-calorie malnutrition** (E44.0). Undernutrition raises the risk of poor outcomes and drug toxicity; pyridoxine is needed with isoniazid. **S**

## Recommendations

1. Start today: rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg, and pyrazinamide 1000 mg (weight band 40 to under 55 kg) once daily with food for eight weeks (56 doses), then rifapentine, moxifloxacin, and isoniazid for nine weeks (63 doses), with pyridoxine 50 mg, all by video-observed therapy seven days a week; the regimen is complete at 119 doses, with the intensive phase within 70 days and the whole regimen within five months.
2. No mineral supplements, antacids, or zinc products within four hours before or eight hours after the dose; review any new medicine for interactions with rifapentine or for QT effects with moxifloxacin.
3. Liver tests in two to three weeks and at once for hepatitis symptoms; stop the doses and call for ALT above three times the upper limit with symptoms or five times without.
4. Ask about tendon pain and numbness or tingling at every visit; stop moxifloxacin for tendon pain.
5. Three sputum smears in the third week for release from isolation; monthly sputum culture until two are negative, including the two-month culture; send any positive two-month culture for repeat susceptibility testing.
6. Phenotypic susceptibility to rifampin, isoniazid, pyrazinamide, and moxifloxacin on the first isolate; change the regimen if any resistance is found.
7. Sweat chloride test and serum alpha-1 antitrypsin level at the next visit, once he is out of isolation.
8. Dietitian support with supplement drinks taken in the afternoon or evening, away from the dose.
9. No electrocardiogram unless symptoms or a new QT-prolonging medicine arise.
10. I will review the results by message at two months and at the end of treatment; no further infectious diseases visit unless the cultures stay positive, resistance is found, or a drug must be stopped.

## Strengths and supports

- Born in Poland to a French father and a Polish mother; left home at 20 and has not been back; sources of support he names: a close circle of friends from home, his students, and his music **S**

## Communication

Discussed with Dr. Lindqvist, who saw him the same morning, and with the health department tuberculosis nurse who will observe his doses by video. The regimen, its precautions, and the release criteria were explained to Mr. Chopin, who chose the four-month regimen and asked for written advice for his students; the health department will contact them directly. **S**

## Follow-up

Results review by message at two months and at the end of treatment; sooner for liver injury, tendon pain, positive cultures at two months, or resistance. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR)
- Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025), American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America (American Journal of Respiratory and Critical Care Medicine)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017), Cystic Fibrosis Foundation (Journal of Pediatrics)
- American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003), American Thoracic Society and European Respiratory Society (American Journal of Respiratory and Critical Care Medicine)
